Castle Biosciences surged 77.9% after a Zacks upgrade, highlighting how the firm's stock picks outpaced the broader market in recent months.

MO's Helix Innovations is lifting oral tobacco results as nicotine pouch volumes climb, prices rise, and margins expand despite declines in other categories.

Verizon NYSE: VZ is 2025's Dog of the Dow. The Dogs of the Dow list includes the index's top 10 dividend yields, which are expected to outperform the index over the subsequent year, according to popular theory.

Insurers like Radian Group, Cincinnati Financial, American Financial, and Sun Life Financial, which have an impressive dividend history, offer a breather amid volatility.

Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.

NEW YORK, NY / ACCESS Newswire / December 29, 2025 / Global supply chains were built for efficiency, not inspection. For decades, auditability was handled through paperwork, attestations, and trust between counterparties.

First Majestic Silver Corp (NYSE:AG) stock is down 4.9% to trade at $16.56 at last glance, the silver miner struggling as the red-hot safe haven asset pulls back from its record run.

San Diego, California--(Newsfile Corp. - December 29, 2025) - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Cogent Communications Holdings, Inc. (NASDAQ: CCOI) focused on whether Cogent Communications and certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Cogent Communications investigation or if you are a Cogent Communications investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-cogent-communications-holdings-inc-investigation-ccoi.html You can also contact attorneys J.C.

Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001's Promise as a Potential Breakthrough Immunotherapy LAWRENCEVILLE, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) Dear Valued Shareholders, 2025, A Year of Momentum: Advancing Toward a Potential Breakthrough in Ovarian Cancer Treatment As we close out 2025, I am excited to reflect on a year marked by significant clinical progress, robust data validation, and strategic execution that has significantly strengthened IMUNON's position.

DigitalBridge Group Inc (NYSE:DBRG) stock is surging today, last seen up 9.9% at $15.30, after news that Japan-based Softbank is in advanced talks to acquire the company for $4 billion in an effort to expand its AI infrastructure.

HOOD, SOFI and AFRM lead a fintech trio poised to ride AI, mobile growth and lower rates into 2026's digital finance boom.

Cold weather and steady LNG demand lift natural gas prices, putting WMB, LNG, and EE in focus for January 2026.

ADSK's scale, AI monetization and steadier earnings growth make it a safer design SaaS bet than FIG amid rising AI-driven costs.

BP, CVX, XOM, and TTE are using AI to transform energy operations, driving efficiency, emissions cuts and returns.

Investors need to pay close attention to KRC stock based on the movements in the options market lately.

M, BG and TGS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 29, 2025.

Platinum has broken above $2,300, confirming a long-term breakout fueled by rising investment demand and clean energy growth, setting the stage for a potential surge toward $3,000 in 2026.

MINNEAPOLIS--(BUSINESS WIRE)--Xcel Energy employees, contractors and retirees, supported by the company's Foundation, provided over $14 million and tens of thousands of volunteer hours in 2025 to support charitable organizations and causes. Throughout the year, they embraced opportunities to donate their time and act on a shared commitment to making a difference in their communities, volunteering nearly 60,000 hours. The Foundation expanded its giving impact this year by investing nearly $5 mil.

Ocugen rises 75% YTD as it advances three gene therapies, with multiple phase II/III readouts and filings lined up for 2026.

The consensus price target hints at a 32.1% upside potential for nCino (NCNO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.